When can we be confident of surgical cure with ctDNA?
- PMID: 35798966
- DOI: 10.1038/s41571-022-00664-8
When can we be confident of surgical cure with ctDNA?
Comment on
-
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer.Cancer Discov. 2022 Jul 6;12(7):1690-1701. doi: 10.1158/2159-8290.CD-21-1486. Cancer Discov. 2022. PMID: 35543554 Free PMC article.
References
-
- Wan, J. C. M. et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat. Rev. Cancer 17, 223–238 (2017). - DOI
-
- Sun, K., Jiang, P., Chan, K. C. A. & Lo, Y. M. D. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc. Natl Acad. Sci. USA 112, E5503–E5512 (2015). - DOI
-
- Moding, E. J., Nabet, B. Y., Alizadeh, A. A. & Diehn, M. Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease. Cancer Discov. 11, 2968–2986 (2021). - DOI
-
- Abbosh, C., Birkbak, N. J. & Swanton, C. Early stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection. Nat. Rev. Clin. Oncol. 15, 577–586 (2018). - DOI
-
- Zhang, J.-T. et al. Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-21-1486 (2022). - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
